The words should help—not become another barrier.

A gene involved in chromatin regulation. Disease-causing variants are associated with an autosomal dominant syndromic neurodevelopmental disorder.

The person’s defined usual function and context before a change or comparison window.

DNA together with associated proteins and chemical marks that help regulate genome organization and gene activity.

A total whose mutually exclusive states account for the complete eligible group, such as information available plus information not recorded equaling all 61 connected people.

Another molecular or clinical finding retained because it may affect interpretation of a record.

The 61 people and families whose information is currently represented in group-level summaries on this site.

Consent, contact, source ownership, translation, or sharing status.

A deletion or duplication affecting a genomic interval that may include ASH1L and sometimes other genes.

A change not detected in tested parental samples, subject to identity, sample, and assay limits.

Attributing a new symptom, behavior, or functional change to an existing diagnosis without proportionate assessment of other explanations.

Records from related people are linked so relatives are not treated as independent recurrence events.

Caregiver-observed function, timing, change, context, or recovery.

A clinical result described by a family before the original record is available.

A position on histone H3 that can carry methyl marks involved in chromatin regulation; ASH1L has H3K36 methyltransferase activity in experimental systems.

A disease mechanism in which one functional copy of a gene is not sufficient for typical function.

The reviewed records contain some information relevant to a defined field or clinical area.

The reported change is also detected in a biological parent or linked family member under the laboratory’s testing framework.

Institutional review and oversight for research involving people, data, or biospecimens under applicable rules.

A structured sequence linking context or load, an observable event, time-matched measurement, action, and return toward baseline.

A molecular consequence expected to reduce or disrupt normal gene product, subject to transcript, position, and variant-specific interpretation.

A sequence change that replaces one amino acid with another.

An exact molecular result is recorded in the information available to this project.

A cellular RNA-surveillance process that can reduce transcripts containing certain premature stop signals.

The reviewed records do not contain an answer for that field or clinical area.

A direct report, laboratory result, imaging study, EEG, examination, or other primary clinical source.

At least one relevant original clinical or laboratory record is available for that person and clinical area.

The proportion of people with a defined genotype who meet a clearly defined phenotype under adequate ascertainment.

Observable or measurable characteristics, functions, diagnoses, and clinical findings.

Video, photograph, audio, or other visible material that may support review when context and permission are established.

A proposed explanation or testable research question kept separate from observations and measurements.

The catalytic protein region central to ASH1L histone-methyltransferase activity.

A working description for a demonstrated ability that is not expressed reliably across different body, brain, task, or environmental states.

The RNA reference sequence used to describe a genetic change and derive its cDNA and protein consequence.

A record with a usable protein consequence eligible for amino-acid position, domain, and exact-recurrence analysis.

Differences in which features appear, their degree, timing, or impact among people with a related genetic condition.

A laboratory classification used when current evidence is insufficient or conflicting.